2025 fourth_quarter Filing
Q4Income
$40K
Filed
January 10, 2026
Lobbying Activities
Health IssuesView all
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases. Reauthorization of the Pediatric Rare Disease Priority Review Voucher Program.
Contacted:HOUSE OF REPRESENTATIVES, SENATE
Lobbyists (3)
ROBERT CLAYTON ALSPACH
Chief Health Counsel for Chairman - House E&C Committee (E&C);Counsel - E&C, Clerk - E&C, and Paid Intern - E&C
JOSH TRENT
Chief Health Counsel for Chairman - House E&C Committee (E&C); Deputy Chief Health Counsel - E&C; Professional Staff - E&C; Health Care Policy Advisor - Senate; Deputy Director Office of Refugee Resettlement HHS; WH Office of Presidential Personnel
mrs SHANNON ROHN DEERE